Effect of osimertinib combined with aspirin on survival period in advanced lung adenocarcinoma patients with EGFR mutation
10.3969/j.issn.1671-8348.2024.13.016
- VernacularTitle:奥希替尼联合阿司匹林对晚期肺腺癌EGFR突变患者生存期的影响
- Author:
Yan LUO
1
;
Lan YAO
;
Zhonghui BAO
;
Yi JIANG
;
Yanxia NI
;
Qin HUANG
;
Shaolin LI
;
Hongbo REN
;
Biyou HUANG
Author Information
1. 重庆市巴南区第二人民医院肿瘤科,重庆 400054
- Keywords:
non-small cell lung cancer;
lung adenocarcinoma;
epidermal growth factor receptor;
tyrosine kinase inhibitors;
osimertinib;
aspirin;
survival period
- From:
Chongqing Medicine
2024;53(13):2011-2015
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of osimertinib combined with aspirin on the survival pe-riod of the advanced lung adenocarcinoma patients with epidermal growth factor receptor(EGFR)mutation.Methods Sixty lung adenocarcinoma patients with EGFR mutation in advanced non-small cell lung cancer(NSCLC)first diagnosed in Banan District Second People's Hospital of from August 2020 to October 2021 were selected as the study subjects and divided into the observation group and control group by the random number table method,30 cases in each group.The observation group adopted osimertinib combined with aspi-rin,and the control used osimertinib merely.The overall response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and the adverse reactions occurrence were compared between the two groups.Results ORR and DCR after 3,6,12 months medication in the observation group were higher than those in the control group,but the differences were not statistically significant(P＞0.05).Compared with the control group,PFS and OS in the observation group were longer,and the differences were statistically significant[14.9(11.8,17.2)m vs.10.5(8.9,12.5)m;24.1(19.5,27.4)m vs.18.1(16.1,21.1)m,P＜0.05].In addition,PFS and OS in male and female patients with brain metastasis,EGER19 and 21 ex-on mutation in the observation group were longer than those in the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in overall and≥Ⅲ degree adverse reactions between the two groups(P＞0.05).Conclusion Osimertinib combined with aspirin could prolong PFS and OS of the advanced lung adenocarcinoma patients with EGFR mutation without increasing the risk of adverse reactions.
